Cargando…
Innovative Therapeutic Approaches for Huntington’s Disease: From Nucleic Acids to GPCR-Targeting Small Molecules
Huntington’s disease (HD) is a fatal neurodegenerative disorder due to an extraordinarily expanded CAG repeat in the huntingtin gene that confers a gain-of-toxic function in the mutant protein. There is currently no effective cure that attenuates progression and severity of the disease. Since HD is...
Autor principal: | Komatsu, Hidetoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662694/ https://www.ncbi.nlm.nih.gov/pubmed/34899193 http://dx.doi.org/10.3389/fncel.2021.785703 |
Ejemplares similares
-
MicroRNAs in Huntington’s Disease: Diagnostic Biomarkers or Therapeutic Agents?
por: Dong, Xiaoyu, et al.
Publicado: (2021) -
Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics
por: Pérez-Arancibia, Rodrigo, et al.
Publicado: (2023) -
The Ion Channel and GPCR Toolkit of Brain Capillary Pericytes
por: Hariharan, Ashwini, et al.
Publicado: (2020) -
The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington’s Disease
por: Bhat, Shahnawaz Ali, et al.
Publicado: (2023) -
Editorial: GPCR and G Protein-Mediated Signalling Events in the Nervous System
por: Berchiche, Yamina A., et al.
Publicado: (2022)